Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio M Borgia

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Canadian Journal of Gastroenterology & Hepatology|April 10, 2015
Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in CanadaSergio M Borgia, Adenike Rowaiye
Medical Mycology|October 31, 2006
Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimenSergio M Borgia, Jeffrey D Fuller, Alicia Sarabia, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Hepatitis C direct-acting antiviral outcomes in patients 75 years and olderParmvir Parmar, Stephen D Shafran, Sergio M Borgia, et al.
The Journal of Infectious Diseases|July 9, 2018
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 GenotypesSergio M Borgia, Charlotte Hedskog, Bandita Parhy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2021
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian RegistryFernanda Q Onofrio, Curtis Cooper, Sergio M Borgia, et al.
Open Forum Infectious Diseases|April 6, 2019
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV ClassificationCharlotte Hedskog, Bandita Parhy, Silvia Chang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsAlessandra Mangia, Scott Milligan, Mandana Khalili, et al.
Viruses|November 24, 2022
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health DisordersHeiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, et al.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Canadian Journal of Gastroenterology & Hepatology|April 10, 2015
Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in CanadaSergio M Borgia, Adenike Rowaiye
Medical Mycology|October 31, 2006
Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimenSergio M Borgia, Jeffrey D Fuller, Alicia Sarabia, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Hepatitis C direct-acting antiviral outcomes in patients 75 years and olderParmvir Parmar, Stephen D Shafran, Sergio M Borgia, et al.
The Journal of Infectious Diseases|July 9, 2018
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 GenotypesSergio M Borgia, Charlotte Hedskog, Bandita Parhy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2021
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian RegistryFernanda Q Onofrio, Curtis Cooper, Sergio M Borgia, et al.
Open Forum Infectious Diseases|April 6, 2019
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV ClassificationCharlotte Hedskog, Bandita Parhy, Silvia Chang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsAlessandra Mangia, Scott Milligan, Mandana Khalili, et al.
Viruses|November 24, 2022
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health DisordersHeiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, et al.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Pageof 2